MAIA BIOTECHNOLOGY INC
MAIANYSE AMERICANTrading Snapshot
- Day Range
- $450.33 – $458.63
- 52-Week Range
- $0.87 – $3.19
- Volume
- $3.02B
- Avg Volume
- $3.01B
- Shares Outstanding
- 60.8M
- Next Earnings
- Dec 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $1M
- P/E Ratio
- -1.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.44
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +22.8%
Why Investors Own MAIA
- ✓High-growth profile — revenue up -3.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MAIA BIOTECHNOLOGY INC
MAIA
StockOtter · stockotter.spaceAbout MAIA BIOTECHNOLOGY INC
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open Interest
Seth Fiegerman says Meta is moving aggressively into AI agents, with a new enterprise product that looks like a ‘Muse'-style assistant for workplace use. He notes that the company's push suggests the focus is shifting fr
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company f
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control ra
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today annou
MAIA: Tiffany Wilding Says Labor Costs Are Easing, Supporting Fed Patience, ft. Tiffany Wilding
PIMCO economist Tiffany Wilding said labor markets are no longer a major source of inflation pressure, pointing to broad measures of nominal wage inflation that have been decelerating. She argued that AI, demographic shi